Login
Companies $ALT
$1.55 -$0.01 (0.6%) After hours
Altimmune, Inc. logo

Altimmune, Inc.

altimmune.com

What Do They Do?

Develops pemvidutide, an investigational therapy for serious liver diseases, for patients with MASH, alcohol use disorder and alcohol-associated liver disease.

How Do They Make Money?

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $88.1M in FY2025.

Operating income, FY2025
−230461% of revenue
▲ +8% (Loss) vs FY2024 (−$103.2M, −515860%)
Net income, FY2025
−214861% of revenue
▲ +7% (Loss) vs FY2024 (−$95.1M, −475295%)
Free cash flow, FY2025
−164746% of revenue
▲ +15% (Loss) vs FY2024 (−$79.8M, −399240%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −66% (Loss)
vs −$19M in Q3 FY2025
  • Jul 28, 2026 Pemvidutide met the main endpoint in an alcohol use disorder trial The company plans to meet with the FDA to discuss the program's next steps.

Shrinking. Revenue fell 99% in 4 years, from $4.4M in FY2021 to $41K in FY2025, about 69% a year.

Focus on liver diseases The older report described pemvidutide for obesity and non-alcoholic steatohepatitis and also listed a hepatitis B candidate. The latest report focuses on pemvidutide for MASH, alcohol use disorder and alcohol-associated liver disease.

Who Do They Compete With?

Competes with Eli Lilly, Roche, Novo Nordisk, Pfizer, AstraZeneca, Amgen, Boehringer Ingelheim, Merck, Madrigal Pharmaceuticals, Aligos, Viking Therapeutics, GSK, Merck/Hanmi Pharmaceutical, Inventiva, Sagimet, Apollo Therapeutics Group Limited/HEC Pharma, Gilead, Alkermes, Adial, and Imbrium

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support